Drug Targeting Organ-Specific Strategies

References 305
[16] Milstein C, Waldmann H, Curr. Opin. Immunol. 1999, 11, 589–591.
[17] Hudson PJ, Curr. Opin. Immunol. 1999, 11, 548–557.
[18] Colcher D, Pavlinkova G, Beresford G, Booth BJ, Choudhury A, Batra SK, Q. J. Nucl. Med. 1998,
42, 225–241.
[19] Wagner E, Curiel D, Cotten M, Adv. Drug Deliv. Rev. 1994, 14, 113–135.
[20] Pardridge WM, Adv. Drug Deliv. Rev. 1999, 36, 299–321.
[21] Feener EP, King GL, Adv. Drug Deliv. Rev. 1998, 29, 197–213.
[22] Fiume L, Busi C, Di Stefano G, Mattioli A, Adv. Drug Deliv. Rev. 1994, 14, 51–65.
[23] Schwartz AL, CRC. Crit. Rev. Biochem. 1984, 16, 207–223.
[24] Van der Sluijs P, Meijer DKF, In: Liver Diseases. Targeted Diagnosis and Therapy Using Specific
Receptors and Ligands (Eds Wu GY, Wu CH), pp. 235–264. Marcel Dekker, Inc., New York,
1991.
[25] Wadhwa MS, Rice KG, J. Drug Target. 1995, 3, 111–127.
[26] Stowell CP, Lee YC, Adv. Carbohydr. Chem. Biochem. 1980, 37, 225–281.
[27] Monsigny M, Roche A-C, Midoux P, Mayer R, Adv. Drug Deliv. Rev. 1994, 14, 1–24.
[28] Gabius S, Kayser K, Bovin NV, Yamazaki N, Kojima S, Kaltner H, Gabius H-J, Eur. J. Pharm.
Biopharm. 1996, 42, 250–261
[29] Lerchen HG, Baumgarten J, Piel N, Kolb-Bachofen V, Angew. Chem. Int. Ed. Engl. 1999, 38,
3680–3683.
[30] Weikert S, Papac D, Briggs J, Cowfer D, Tom S, Gawlitzek M, Lofgren J, Mehta S, Chisholm V,
Modi N, Eppler S, Carroll K, Chamow S, Peers D, Berman P, Krummen L, Nature Biotechnol.
1999, 17, 1116–1121.
[31] Mulligan MS, Warner RL, Rittershaus CW, Thomas LJ, Ryan US, Foreman KE, Crouch LD, Till
GO, Ward PA, J. Immunol. 1999, 162, 4952–4959.
[32] Sudimack J, Lee RJ, Adv. Drug Deliv. Rev. 2000, 41, 147–162.
[33] Beljaars L, Molema G, Schuppan D, Geerts A, De Bleser PJ, Weert B, Meijer DKF, J. Biol.
Chem. 2000, 275, 12743–12751.
[34] Koivunen E, Wang B, Ruoslahti E, Biotechnology (NY) 1995, 13, 265–270.
[35] Samoylova TI, Smith BF, Muscle Nerve 1999, 22, 460–466.
[36] Burg MA, Pasqualini R, Arap W, Ruoslahti E, Stallcup WB, Cancer Res. 1999, 59, 2869–2874.
[37] Rajotte D, Ruoslahti E, J. Biol. Chem. 1999, 274, 11593–11598.
[38] Martens CL, Cwirla SE, Lee RY, Whitehorn E, Chen EY, Bakker A, Martin EL, Wagstrom C,
Gopalan P, Smith CW, et al., J. Biol. Chem. 1995, 270, 21129–21136.
[39] Arap W, Pasqualini R, Ruoslahti E, Science 1998, 279, 377–380.
[40] Ellerby HM, Arap W, Ellerby LM, Kain R, Andrusiak R, Del Rio G, Krajewski S, Lombardo CR,
Rao R, Ruoslahti E, Bredesen DE, Pasqualini R, Nature Med. 1999, 5, 1032–1038.
[41] Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A, Ashmun RA, Shapiro
LH, Arap W, Ruoslahti E, Cancer Res. 2000, 60, 722–727.
[42] Mao S, Gao C, Lo CH, Wirsching P, Wong CH, Janda KD, Proc. Natl Acad. Sci. USA 1999, 96,
6953–6958.
[43] Ruoslahti E, Annu. Rev. Cell Dev. Biol. 1996, 12, 697–715.
[44] Furitsu H, Ogawara K, Fujita T, Yamashita F, Takakura Y, Sezaki H, Hashida M, Int. J. Pharm.
1997, 151, 15–26.
[45] Kok RJ, Grijpstra F, Nederhoed KH, Moolenaar F, De Zeeuw D, Meijer DKF, Drug Delivery
1999, 6, 1–8.
[46] Swart PJ, Hirano T, Kuipers ME, Ito Y, Smit C, Hashida M, Nishikawa M, Beljaars L, Meijer
DKF, Poelstra K, J. Hepatol. 1999, 30, 1034–1043.
[47] Inoue M, Methods Enzymol. 1994, 233, 212–221.
[48] Jansen RW, Molema G, Pauwels R, Schols D, De Clercq E, Meijer DKF, Mol. Pharmacol. 1991,
39, 818–823.
[49] Kuipers ME, Swart PJ, Witvrouw M, Esté JA, Reymen D, De Clercq E, Meijer DKF, J. Drug Target.
1999, 6, 323–335.
[50] Swart PJ, Beljaars E, Smit C, Pasma A, Schuitemaker H, Meijer DKF, J. Drug Target. 1996, 4,
109–116.
[51] Swart PJ, Beljaars L, Kuipers ME, Smit C, Nieuwenhuis P, Meijer DKF, Biochem. Pharmacol.
1999, 58, 1425–1435.
[52] Lloyd JB, Adv. Drug Deliv. Rev. 2000, 41, 189–200.
[53] Bodor N, J. Control. Rel. 1999, 62, 209–222.
[54] Eto T, Takahashi H, Nature Med. 1999, 5, 577–581.